Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II evaluation of ifosfamide plus doxorubicin and filgrastim versus gemcitabine plus docetaxel and filgrastim in the treatment of localized poor prognosis soft tissue sarcoma.

Next Previous
X
Search
Trial Profile

Phase II evaluation of ifosfamide plus doxorubicin and filgrastim versus gemcitabine plus docetaxel and filgrastim in the treatment of localized poor prognosis soft tissue sarcoma.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel; Doxorubicin; Gemcitabine; Ifosfamide
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Dec 2015 Biomarkers information updated
    • 04 Jun 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 04 Jun 2013 Trial rationale and design presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top